Navigation Links
AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Date:10/19/2009

QUEBEC CITY, Oct. 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, announced today that it has received commitments to purchase US$5.5 million of units comprised of common shares and common share purchase warrants in a registered direct offering. Under the terms of a Securities Purchase Agreement, the Company will sell to such institutional investors an aggregate of approximately 4.58 million common shares of its capital at a price of US$1.20 per share and issue warrants to acquire an aggregate of approximately 1.83 million common shares at an exercise price of US$1.25 per share.

The warrants to purchase additional common shares of AEterna Zentaris will be immediately exercisable upon issuance and will expire five years after issuance. All of the common shares and warrants were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used for general corporate purposes, including clinical development of our leading compounds. The offering is expected to be consummated no later than October 22, 2009, subject to customary closing conditions.

In connection with the offering, the Company will file a prospectus supplement to its existing base shelf prospectus with the Canadian securities regulatory authorities and with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company or by contacting AEterna Zentaris Inc., 1405 du Parc-Technologique Boulevard, Quebec City, Canada G1P 4P5.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of such securities in any jurisdiction in which such offer,
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
2. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
3. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
4. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
5. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
7. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
8. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
9. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
10. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
11. AEterna Zentaris Receives US$10 Million from Institutional Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/19/2014)... December 19, 2014 Bioject Medical ... and manufacturer of needle-free injection technology, today announced ... Immunomic Therapeutics, Inc. (“ITI”) for ITI to use ... its LAMP™ vaccine platform. , In the ... Worldwide license to the Biojector®-2000 that triggers based ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... economic development in Dane County, Madison Gas & ... last 20 years as it works to nurture entrepreneurial ... tomorrow's major league employers. , ,For MG&E, it's part ... creating the right conditions for entrepreneurs by providing financial ...
... completed its previously announced acquisition of MARC Global Holdings, ... to 738 employees at 21 sites with $172 million ... MARC. , ,Former MARC CEO Oliver Cooper will have ... company leader John Jazwiec. , ,"The integration of MARC ...
... are pushing state restrictions on human embryonic stem ... beyond President Bush's 2001 order and put Wisconsin's ... ,Rather than adding a layer of unnecessary regulation, ... -- one federal and the other international -- ...
Cached Biology Technology:How MG&E bets on small companies for the long term 2How MG&E bets on small companies for the long term 3How MG&E bets on small companies for the long term 4Federal and global guidelines on stem cell research offer a level playing field 2Federal and global guidelines on stem cell research offer a level playing field 3
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season ... industry as Acuity Market Intelligence reports that the ... be open. Acuity forecasts that intensifying demand for ... incorporate biometrics will drive a global market of ... devices by 2020.   According to ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems ... http://photos.prnewswire.com/prnh/20130307/600769 The North American ... CAGR of 3.6% from 2014 to 2019. Although the ... Canada is expected to grow ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ... its team and bring LaunchKey to market in 2015. ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... conditions in California could be a gold mine to ... relationships and how these inner workings might apply on ... today on Science Online, researchers from the Department of ... California Berkeley describe a bacterial community that flourishes in ...
... shape the growth of engineered tissueCollagen often pops up ... collagen with a molecular hitchhiker, materials scientists at Johns ... researchers have found a simple new way to modify ... a treatment to block the formation of unwanted scar ...
... the marine bacterium Colwellia psychrerythraea 34H keeps very cool--typically ... in this frigid environment? To find out, scientists at ... sequenced and analyzed C. psychrerythraea's genome. , That genome ... of Sciences (PNAS) Online Early Edition July 25-29, reveals ...
Cached Biology News:ORNL, UC Berkeley unravel real-world clues to Earth's mysteries 2ORNL, UC Berkeley unravel real-world clues to Earth's mysteries 3Modified collagen could yield important medical applications 2Modified collagen could yield important medical applications 3Deep thinking: Scientists sequence a cold-loving marine microbe 2Deep thinking: Scientists sequence a cold-loving marine microbe 3